CAR-T Cell Immunotherapy for HCC Targeting GPC3

NCT02723942 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Project terminated due to revision of local regulations

Conditions

GPC3 Positive Hepatocellular Carcinoma
CAR-T Cell Immunotherapy

Interventions

BIOLOGICAL: CAR-T cell immunotherapy

Sponsor

Fuda Cancer Hospital, Guangzhou